Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
information fournie par Boursorama CP 24/09/2026 à 17:45
Ajouter Boursorama à vos sources

2026 Half-Year Results and Business Update

myvac® – Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing

TG4050 – First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform advancing in resected HNSCC

TG4070 – Second novel myvac®-based INTV in early-stage NSCLC , with potential to be applied across multiple early-stage solid tumor types

Positive preclinical data from TG-MVATM, a new generation of prophylactic vaccine against mpox and smallpox based on MVA vector

Business funded until early 2028

Valeurs associées

TRANSGENE
0,8100 EUR Euronext Paris -4,37%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
106,88 +3,46%
HAFFNER ENERGY
0,79 +10,18%
CAC 40
8 081,43 -0,52%
GENFIT
9,05 -11,27%
TOTALENERGIES
81,05 +1,80%
Chargement...

Pages les plus populaires

L'offre BoursoBank